Join our daily newsletter At The Bell to receive exclusive market insights
- NeuroScientific Biopharmaceuticals (NSB) CEO and Managing Director Matt Liddelow resigns from the company, effective immediately
- The news comes just 48 hours after NSB’s announcement its phase one clinical trial for EmtinB was rejected by the Human Research Ethics Committee (HREC), citing a lack of supporting documentation
- NeuroScientific told investors a rebuild of the company is now underway
- NSB will now commence a domestic and international search for its next CEO with pharmaceutical development experience
- NSB shares are up 13.6 per cent to trade at 10 cents at 12:27 pm AEST
NeuroScientific Biopharmaceuticals (NSB) CEO and Managing Director has resigned from the company, effective immediately.
Matt Liddelow served the company for more than four years.
The news comes just 48 hours after NSB’s announcement that its phase one clinical trial for EmtinB was rejected by the Human Research Ethics Committee (HREC), citing a lack of supporting documentation.
“I acknowledge the loss in shareholder value as a result of the rejected Human Research Ethics Committee submission and I will work tirelessly with my NSB colleagues to do what we can to get EmtinB into a phase one clinical trial as quickly as possible,” NeuroScientific Biopharmaceuticals Chair Paul Rennie said.
“A rebuild of the company is underway and I appreciate the support of all investors who have remained with us.”
The company said it will commence a domestic and international search for its next Chief Executive Officer with pharmaceutical development experience.
“Together with the senior management team, we will commence a review of operations and make whatever changes we need to make to ensure our lead asset EmtinB continues to progress to commercialisation,” Mr Rennie concluded.
NeuroScientific Biopharmaceuticals shares were up 13.6 per cent to trade at 10 cents at 12:27 pm AEST.
